Companies › ABX advanced biochemical compounds
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [18F]PSMA-1007 PSMA-targeted PET imaging agent (fluorine-18 labeled small molecule) | FOLH1 | Phase 3 | Prostate Cancer | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06122584 | [18F]PSMA-1007 | Phase 3 | Prostate Cancer | Oncology | Mar 2027 |
Curium US Fusion Pharmaceuticals Clarity Pharmaceuticals LaNova Medicines Zhejiang Quetzal Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.